SCHEMBL8520737

SCHEMBL8520737

O=P(O)(CCc1cccc2ccccc12)Oc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ACP3 P15309 1/20 0.53
TDP1 Q9NUW8 1/20 0.46
SRC P12931 1/20 0.44
MTNR1A P48039 2/20 0.43
AKR1B1 P15121 2/20 0.43
FFAR1 O14842 1/20 0.43
CETP P11597 1/20 0.42
TRPV1 Q8NER1 1/20 0.41
CYP1A2 P05177 1/20 0.41
MCL1 Q07820 2/20 0.41
MAPT P10636 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CTNNB1 P35222 1/20 0.40
NQO2 P16083 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8048486 0.93 ACP3 (0.49) ACP3TDP1SRCMTNR1AAKR1B1
SCHEMBL7639813 0.92 ACP3 (0.48) ACP3TDP1SRCMTNR1AAKR1B1
SCHEMBL7605396 0.86 ACP3 (0.63) ACP3TDP1SRCAKR1B1FFAR1
SCHEMBL27811913 0.80 ACP3 (0.68) ACP3TDP1MTNR1ACYP1A2MCL1
SCHEMBL8520179 0.79 SRC (0.39) SRCCYP1A2MCL1MAPTNPC1
SCHEMBL28278348 0.78 ACP3 (0.44) ACP3TDP1MTNR1AAKR1B1FFAR1
SCHEMBL5059954 0.77 ACP3 (0.44) ACP3TDP1MTNR1AAKR1B1FFAR1
SCHEMBL11772534 0.77 SRC (0.57) TDP1SRCCETPL3MBTL1
SCHEMBL3245338 0.76 SRC (0.61) TDP1SRCCETPL3MBTL1
SCHEMBL7634441 0.75 FAAH (0.54) CYP1A2MAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0949922-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 1999-10-20 EP disclosed
WO-1998013044-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 1998-04-02 WO disclosed